📜 What This Document Is 📄

This filing is a Form S-1 Registration Statement, which is a critical document that companies must file with the U.S. Securities and Exchange Commission (SEC) before they can sell securities to the public. It acts like a detailed public disclosure of the company's operations, financial risks, and overall strategy.

The purpose of this specific S-1 filing is for CytoDyn Inc. to register the resale of existing common stock and associated warrants by its current selling stockholders. 👉 Because it is a resale registration, the company itself is not selling shares and will not receive revenue from the shares sold, though it will receive funds if the warrants attached to those shares are exercised in cash.

🏢 What CytoDyn Inc. Does 🧬

CytoDyn is a clinical-stage biotechnology company. In simple terms, it is a pharmaceutical developer that focuses on bringing specialized drug candidates to market. The core of its business model is research and development (R&D) to discover, test, and eventually commercialize therapeutics.

The company's entire operational strategy is currently centered on one primary drug candidate: leronlimab. 👉 This means that the current success, financial health, and future value of the company are almost entirely dependent on the successful development, regulatory approval, and eventual commercialization of leronlimab.

🔬 The Focus on Leronlimab 🎯

Leronlimab is the central asset driving CytoDyn's entire value proposition. The company has invested significant resources into developing this drug to treat specific types of cancer.

• Primary Indications: Leronlimab was initially developed for patients with relapsed/refractory microsatellite stable colorectal cancer.
• Pipeline Potential: The company is also exploring its therapeutic potential for other solid-tumor oncology indications, including metastatic triple-negative breast cancer.
• Major Agreements: The company has entered into agreements with major entities, including Progenics Pharmaceuticals, Inc. and Lonza Sales AG. These agreements involve paying significant milestone payments, licensing fees, and royalties, which are necessary to advance the drug. 👉 The necessity to make significant milestone payments and royalties based on these agreements means that CytoDyn requires continuous additional financing to keep the drug candidate moving forward.

⚠️ Critical Financial Risks and Cash Needs 📉

The filing contains extreme warnings regarding CytoDyn's financial standing. The overarching theme is that the company is highly cash-dependent and faces immediate, significant financial risks.

• Low Cash Reserves: As of April 15, 2026, the company reported an unrestricted cash balance of approximately $13.4 million. It also had no reserved cash balance.
• Need for Financing: The company states that it does not expect to receive substantial, if any, revenues in the foreseeable future, meaning it must continuously raise substantial additional financing to cover operating expenses and payment obligations.
• Going Concern Risk: The report explicitly notes that the company's auditors have issued a going concern opinion. This is a serious warning, meaning that the auditors have determined there is substantial doubt that the company can continue as an ongoing business for the next 12 months without securing adequate financing.
• Stock Price Challenge: The low trading price of the common stock (which was at $0.34 per share on April 15, 2026) presents a significant hurdle, making it extremely difficult for the company to raise needed funds.
• Future Losses: The company has a history of significant operating losses and expects to continue incurring operating losses, as it has not generated any revenue from product sales, licensing, or other income opportunities to date.

💰 Shares and Securities Being Resold 📑

A large portion of the filing details the complex capitalization structure, which involves various types of equity, warrants, and preferred stock.

• Total Shares Registered: The selling stockholders are registering a remaining aggregate of 278,076,375 shares of common stock.
• Specific Securities: These shares include 184,135,636 shares of common stock and 93,940,739 shares underlying outstanding warrants to purchase common stock.
• Dilution Risk: The overall financial environment, combined with the need to raise continuous capital, is expected to lead to dilution—which means existing stockholders' ownership percentage will shrink, potentially negatively affecting the stock price.
• Complexity: The company has been involved in numerous transactions involving different types of notes, convertible preferred stock (Series B, C, and D), warrants, and private placements over several years, making its capital structure highly complex.

🚨 Key Operational and Development Risks 🚧

The risks related to the company's operations are overwhelming, centered on the drug itself, the regulatory environment, and the management team.

• Regulatory Approval: The ability to commercialize leronlimab is the largest hurdle. Approval from the FDA (or foreign regulators) is not guaranteed. The drug must prove safety and efficacy through clinical trials, and the regulatory process is extremely challenging and subject to significant, unpredictable changes.
• Development Dependence: The business is entirely dependent on the success of leronlimab. Failure to complete clinical development, obtain market approval, or successfully commercialize the drug will materially and adversely affect the company.
• Operational Capacity: The company relies heavily on third parties, including Clinical Research Organizations (CROs) and external manufacturers, for conducting trials and producing supplies. Any failure by these third parties to perform their duties could stop the development process.
• Management Team: The success of the company is highly dependent on the skills and dedication of its officers, directors, and key scientific advisors. Losing these individuals or failing to attract new talent can negatively impact drug development.

⚖️ Legal and Corporate Governance Concerns 🧑‍⚖️

CytoDyn faces significant risks stemming from legal challenges and the need for internal controls.

• Litigation: The company is exposed to various legal risks, including potential class-action lawsuits and derivative actions filed by stockholders. Such litigation can divert management attention and is costly, regardless of the outcome.
• Internal Controls: The company must maintain a robust system of internal control over financial reporting. Failure in this area—or inability to manage technological failures or cyber-based attacks—could lead to inaccurate reporting, negatively affecting the stock price and operations.
• Patent Risks: The company's success hinges on maintaining intellectual property protection. Legal challenges concerning patent rights (either by CytoDyn or third parties) could cause severe delays or financial loss.

📞 Where to Find More Information ℹ️

If you wish to investigate CytoDyn's position further, the following contacts and resource notes were provided in the filing:

• Principal Executive Offices: 1111 Main Street, Suite 660 Vancouver, Washington 98660.
• General Contact: (360) 980-8524.
• Agent for Service (SEC): Mary Ann Frantz, Miller Nash LLP, 1140 SW Washington St, Suite 700 Portland, Oregon 97205.

---

🧠 The Analogy

Buying CytoDyn's stock today is like investing in a brilliant, highly promising engine (leronlimab) that could revolutionize transportation, but the owner of the company (CytoDyn) has run out of oil and needs constant, massive infusions of cash just to keep the engine idling. You are buying a share of the potential for a revolutionary drug, but that potential is balanced by immense, immediate financial risk, continuous need for external funding, and the uncertainty of regulatory "roadblocks."

🧩 Final Takeaway

CytoDyn is a high-stakes, single-product bet. The company is highly cash-constrained, and while leronlimab is a strong asset, its commercialization is dependent on successfully navigating years of expensive clinical trials, overcoming regulatory uncertainty, and securing continuous, large-scale financing from outside investors.